Article

Soy Diet Worsens Heart Disease in Mice

Department of Medicine, Division of Cardiology, University of Colorado Health Sciences Center, Denver, Colorado, USA.
Journal of Clinical Investigation (Impact Factor: 13.22). 02/2006; 116(1):209-16. DOI: 10.1172/JCI24676
Source: PubMed

ABSTRACT

We report that dietary modification from a soy-based diet to a casein-based diet radically improves disease indicators and cardiac function in a transgenic mouse model of hypertrophic cardiomyopathy. On a soy diet, males with a mutation in the alpha-myosin heavy chain gene progress to dilation and heart failure. However, males fed a casein diet no longer deteriorate to severe, dilated cardiomyopathy. Remarkably, their LV size and contractile function are preserved. Further, this diet prevents a number of pathologic indicators in males, including fibrosis, induction of beta-myosin heavy chain, inactivation of glycogen synthase kinase 3beta (GSK3beta), and caspase-3 activation.

Download full-text

Full-text

Available from: John P Konhilas, Dec 23, 2013
  • Source
    • "These results suggest that genistein may afford greater cardioprotection in females than in males. In contrast, soy phytoestrogen supplementation augments cardiac growth in male mice but not in females (Stauffer et al., 2006), and a soy-based diet worsens hypertrophic cardiomyopathy more in male mice than in females (Haines et al., 2012a). These results strongly suggest that caution should be used before recommending estrogenic compound supplementation, at least in patients with cardiac disease (Haines et al., 2012b). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Food and beverage intake is the only behavior that animals, including human beings, must continually repeat in order to provide energy and chemical materials to the body. Recent epidemiological findings are poised to usher the science of nutrition into in a new era in which the consumption of specific whole foods, now called functional foods, is strongly associated with reduced risk of chronic diseases, including cancer and cardiovascular diseases. These findings have led to the hypothesis that specific food components, in particular phenolic compounds, interact with the human organism at the organ, cellular, and molecular levels to trigger a preventive action against chronic diseases. Numerous bioactive compounds have been identified and isolated from fruits, vegetables, and whole grains and are now present in all drugstores as dietary supplements to the usual intake of amino acids, vitamin, botanical compounds, and so on, although much basic information about their action in humans remains limited. For example, no stratification by sex has been performed in studies of their effects. Although human beings are mainly made up of men and women, in recent years it has become accepted that both biological sex and gender are prominent players in health and medicine. Until the last decade of the 20th century, research on women was neglected and results obtained in men were directly translated to women, both in medicine and in nutrition. Different strategies have been developed in order to maintain male and female body homeostasis, implying that there are important differences in the bioavailability, metabolism, distribution, and elimination of bioactive compounds in males and in females. This article will review some of these differences underlying the possibility that plant-derived phenolic compounds can differently influence the health of male and female individuals.
    Full-text · Article · Aug 2014
  • Source
    • "To identify putative AMPK-target specific miRs, we performed a real-time PCR screen using the R403Q transgenic mouse model of HCM to identify disease-associated miRs [22], [23]. R403Q HCM mice express a mutant myosin heavy chain (R403Q) corresponding to a human mutation causing HCM and possess multiple phenotypic similarities with their human counterparts [22], [24]. More importantly, this R403Q model also demonstrates the energetic abnormalities that occur in cardiac disease states [25], [26]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Recently, MicroRNAs (miR) and AMP-kinase (AMPK) have emerged as prominent players in the development of cardiac hypertrophy and heart failure. We hypothesized that components of the adenosine monophosphate-activated kinase (AMPK) pathway are targeted by miRs and alter AMPK signaling during pathological cardiac stress. Using a mouse model of hypertrophic cardiomyopathy (HCM), we demonstrated early elevation of miR-195 and miR-451 in HCM hearts, which targets MO25, a central component of the MO25/STRAD/LKB1 complex that acts as an upstream kinase for AMPK. We show functional targeting of MO25 by miR-195 and -451. Further in vitro interrogation of MO25 as a functional target validated this hypothesis where over-expression of miR-195 in C2C12 cells knocked down MO25 expression levels and downstream AMPK signaling (phosphorylation of Acetyl CoA carboxylase [ACC] and AMPK activity assay), similar to MO25 knockdown in C2C12 cells by siRNA. Parallel changes were measured in 60 day R403Q HCM male hearts that were rescued by short-term administration of AICAR, an AMPK agonist. Elevated miR-195 targets the LKB1/AMPK signaling axis in HCM progression and implicates a functional role in HCM disease progression. MiR-195 may serve as potential therapeutics or therapeutic targets for heart disease.
    Full-text · Article · Jul 2012 · PLoS ONE
  • Source
    • "We have studied sex dimorphisms in R403Q mice and characterized some of the cellular and molecular mechanisms behind the sex differences [43] [92]. These include a number of pathologic indicators such as fibrosis, induction of β-myosin heavy chain, inactivation of glycogen synthase kinase-3β, and activation of proapoptotic pathways in males but not females [43] [92] [94]. Males harboring the R403Q mutation show progressive deterioration in ventricular function associated with chamber dilation whereas females R403Q mice do not [92] [95] [96]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cardiovascular disease (CVD) remains the single leading cause of death in both men and women. A large proportion of the population with CVD will die with a diagnosis of congestive heart failure (CHF). It is becoming increasingly recognized that sex differences exist in the etiology, development, and outcome of CHF. For example, compared to male counterparts, women that present with CHF are typically older and have systolic cardiac function that is not impaired. Despite a growing body of literature addressing the underlying mechanisms of sex dimorphisms in cardiac disease, there remain significant inconsistencies reported in these studies. Given that the development of CHF results from the complex integration of genetic and nongenetic cues, it is not surprising that the elucidation and subsequent identification of molecular mechanisms remains unclear. In this review, key aspects of sex differences in CVD and CHF will be highlighted with an emphasis on some of the unanswered questions regarding these differences. The contention is presented that it becomes critical to reference cellular mechanisms within the context of each sex to better understand these sex dimorphisms.
    Full-text · Article · Apr 2010 · BioMed Research International
Show more